Slow Capital Inc. Acquires 5,346 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Slow Capital Inc. boosted its stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 7.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 82,001 shares of the medical research company's stock after purchasing an additional 5,346 shares during the quarter. Slow Capital Inc.'s holdings in Exact Sciences were worth $4,608,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Chicago Partners Investment Group LLC increased its holdings in shares of Exact Sciences by 1.7% in the third quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company's stock worth $651,000 after acquiring an additional 158 shares in the last quarter. Amalgamated Bank boosted its holdings in Exact Sciences by 2.7% during the second quarter. Amalgamated Bank now owns 10,937 shares of the medical research company's stock worth $462,000 after purchasing an additional 284 shares during the last quarter. Huntington National Bank boosted its holdings in Exact Sciences by 838.1% during the third quarter. Huntington National Bank now owns 394 shares of the medical research company's stock worth $27,000 after purchasing an additional 352 shares during the last quarter. CIBC Asset Management Inc boosted its holdings in Exact Sciences by 6.1% during the third quarter. CIBC Asset Management Inc now owns 6,489 shares of the medical research company's stock worth $442,000 after purchasing an additional 371 shares during the last quarter. Finally, Advisors Asset Management Inc. boosted its holdings in Exact Sciences by 1.4% during the third quarter. Advisors Asset Management Inc. now owns 28,650 shares of the medical research company's stock worth $1,952,000 after purchasing an additional 402 shares during the last quarter. Institutional investors own 88.82% of the company's stock.

Exact Sciences Price Performance

Exact Sciences stock traded down $0.27 during trading hours on Tuesday, reaching $55.41. 1,688,888 shares of the stock were exchanged, compared to its average volume of 2,623,876. The company has a market cap of $10.26 billion, a P/E ratio of -47.36 and a beta of 1.24. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62. The stock has a 50 day moving average of $57.69 and a two-hundred day moving average of $59.75.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The firm had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. The company's revenue for the quarter was up 12.8% compared to the same quarter last year. Equities analysts expect that Exact Sciences Co. will post -1.1 EPS for the current fiscal year.

Insider Activity

In other Exact Sciences news, CEO Kevin T. Conroy bought 19,500 shares of the business's stock in a transaction that occurred on Wednesday, November 13th. The shares were acquired at an average cost of $51.35 per share, for a total transaction of $1,001,325.00. Following the transaction, the chief executive officer now directly owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. This represents a 1.85 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.36% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on EXAS shares. BTIG Research increased their target price on shares of Exact Sciences from $65.00 to $75.00 and gave the stock a "buy" rating in a report on Tuesday, November 26th. Citigroup cut their price target on shares of Exact Sciences from $80.00 to $75.00 and set a "buy" rating for the company in a research note on Wednesday, November 6th. Piper Sandler cut their price target on shares of Exact Sciences from $85.00 to $75.00 and set an "overweight" rating for the company in a research note on Monday, November 11th. TD Cowen increased their price target on shares of Exact Sciences from $82.00 to $86.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Finally, Jefferies Financial Group increased their price target on shares of Exact Sciences from $84.00 to $85.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $72.76.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.